Atlanta, GA, June 12, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the first quarter of fiscal 2023, which ended April 30, 2023.
Fiscal First Quarter 2023 GAAP Financial Results
Total revenue for the first quarter of fiscal 2023 was $5.3 million compared to $5.9 million during the first quarter of fiscal 2022. The change in revenue for the quarter was the result of higher revenue from SaaS and significantly lower professional services revenue. The Company had a large professional services contract not renew at the end of its 2022 fiscal year. This professional services contract is not expected to be part of the Company’s core business going forward. During the first quarter of fiscal 2023, SaaS revenue grew $0.3 million or 12% compared to the first quarter of fiscal 2022.
Net loss for the first quarter of fiscal 2023 was ($2.9) million, compared to a net loss of ($2.8) million during the first quarter of fiscal 2022.
Fiscal First Quarter 2023 Non-GAAP Financial Results
Adjusted EBITDA for the first quarter of fiscal 2023 was ($1.3) million, in line with the first quarter of fiscal 2022. First quarter fiscal 2023 EBITDA adjustments included higher share-based compensation expenses, lower non-cash valuation adjustments and lower acquisition expenses as compared to fiscal first quarter 2022 EBITDA adjustments.
As of April 30, 2023, the Company’s total Booked SaaS Annual Contract Value (“ACV”) was $17.8 million compared to Booked SaaS ACV of $17.2 million as of January 31, 2023. $5.1 million of the Company’s booked SaaS ACV was unimplemented as of April 30, 2023. Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal.
Management Commentary
“We continue to execute against our growth and other corporate goals in fiscal 2023. Our service and innovation teams made significant strides during the first quarter to enable the continued growth of our SaaS revenues, and we believe that our current bookings, once implemented will provide sufficient revenue to achieve breakeven adjusted EBITDA in the third quarter of fiscal 2023.” Stated Tee Green, Chief Executive Officer, Streamline Health. “Health systems are increasingly excited about the opportunity our solutions provide and our ability to ensure they are accurately paid for all of the care they’ve provided.”
Conference Call
The Company will conduct a conference call on Tuesday, June 13, 2023 at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.
A replay of the conference call will be available from Tuesday, June 13, 2023, at 12:00 PM ET to Tuesday, June 20, 2023 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13739290. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Non-GAAP Financial Measures
Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.
Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, share-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table reconciling this measure to “loss from continuing operations” is included in this press release.
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal. Booked SaaS ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. Booked SaaS ACV is not intended to be a replacement for, or forecast of, revenue. There is no GAAP measure comparable to Booked SaaS ACV.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, estimates of anticipated cash flow generation, anticipated bookings, recognition of revenue from contracts included in Booked SaaS ACV, industry trends and market growth, results of investments in sales and marketing, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Company Contact
Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
STREAMLINE HEALTH SOLUTIONS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(rounded to the nearest thousand dollars, except share and per share information)
| Three Months Ended April 30, | ||||||||
| 2023 | 2022 | |||||||
| Revenues: | ||||||||
| Software as a service | $ | 3,175,000 | $ | 2,831,000 | ||||
| Maintenance and support | 1,157,000 | 1,110,000 | ||||||
| Professional fees and licenses | 1,000,000 | 1,994,000 | ||||||
| Total revenues | 5,332,000 | 5,935,000 | ||||||
| Operating expenses: | ||||||||
| Cost of software as a service | 1,589,000 | 1,497,000 | ||||||
| Cost of maintenance and support | 89,000 | 46,000 | ||||||
| Cost of professional fees and licenses | 1,108,000 | 1,666,000 | ||||||
| Selling, general and administrative expense | 3,806,000 | 4,501,000 | ||||||
| Research and development | 1,701,000 | 1,312,000 | ||||||
| Acquisition-related costs | 35,000 | 90,000 | ||||||
| Total operating expenses | 8,328,000 | 9,112,000 | ||||||
| Operating loss | (2,996,000 | ) | (3,177,000 | ) | ||||
| Other (expense) income: | ||||||||
| Interest expense | (248,000 | ) | (132,000 | ) | ||||
| Acquisition earnout valuation adjustments | 364,000 | 500,000 | ||||||
| Other | 32,000 | 33,000 | ||||||
| Loss before income taxes | (2,848,000 | ) | (2,776,000 | ) | ||||
| Income tax expense | (53,000 | ) | (11,000 | ) | ||||
| Net loss | $ | (2,901,000 | ) | $ | (2,787,000 | ) | ||
| Basic and Diluted Earnings Per Share: | ||||||||
| Net loss per common share – basic and diluted | $ | (0.05 | ) | $ | (0.06 | ) | ||
| Weighted average number of common shares – basic and diluted | 55,970,880 | 47,028,463 | ||||||
STREAMLINE HEALTH SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(rounded to the nearest thousand dollars, except share and per share information)
| April 30, 2023 | January 31, 2023 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,987,000 | $ | 6,598,000 | ||||
| Accounts receivable, net of allowance for credit losses of $94,000 and $132,000, respectively | 4,280,000 | 7,719,000 | ||||||
| Contract receivables | 535,000 | 960,000 | ||||||
| Prepaid and other current assets | 717,000 | 710,000 | ||||||
| Total current assets | 11,519,000 | 15,987,000 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net of accumulated amortization of $255,000 and $246,000 respectively | 99,000 | 79,000 | ||||||
| Right-of use asset for operating lease | — | 32,000 | ||||||
| Capitalized software development costs, net of accumulated amortization of $6,659,000 and $6,224,000, respectively | 5,838,000 | 5,846,000 | ||||||
| Intangible assets, net of accumulated amortization of $3,077,000 and $2,627,000, respectively | 14,343,000 | 14,793,000 | ||||||
| Goodwill | 23,089,000 | 23,089,000 | ||||||
| Other | 1,598,000 | 1,695,000 | ||||||
| Total non-current assets | 44,967,000 | 45,534,000 | ||||||
| Total assets | $ | 56,486,000 | $ | 61,521,000 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 299,000 | $ | 626,000 | ||||
| Accrued expenses | 2,505,000 | 3,265,000 | ||||||
| Current portion of term loan | 875,000 | 750,000 | ||||||
| Deferred revenues | 7,382,000 | 8,361,000 | ||||||
| Current portion of operating lease obligation | — | 35,000 | ||||||
| Current portion of acquisition earnout liability | 3,374,000 | 3,738,000 | ||||||
| Total current liabilities | 14,435,000 | 16,775,000 | ||||||
| Non-current liabilities: | ||||||||
| Term loan, net of current portion and deferred financing costs | 8,742,000 | 8,964,000 | ||||||
| Deferred revenues, less current portion | 104,000 | 167,000 | ||||||
| Other non-current liabilities | 143,000 | 104,000 | ||||||
| Total non-current liabilities | 8,989,000 | 9,235,000 | ||||||
| Total liabilities | 23,424,000 | 26,010,000 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock, $0.01 par value per share, 85,000,000 shares authorized; 58,636,411 and 57,567,210 shares issued and outstanding, respectively | 586,000 | 576,000 | ||||||
| Additional paid in capital | 132,379,000 | 131,973,000 | ||||||
| Accumulated deficit | (99,903,000 | ) | (97,038,000 | ) | ||||
| Total stockholders’ equity | 33,062,000 | 35,511,000 | ||||||
| Total liabilities and stockholders’ equity | $ | 56,486,000 | $ | 61,521,000 | ||||
STREAMLINE HEALTH SOLUTIONS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Rounded to the nearest thousand dollars)
| Three Months Ended April 30, | |||||||||
| 2023 | 2022 | ||||||||
| Net loss | $ | (2,901,000 | ) | $ | (2,787,000 | ) | |||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||||||||
| Depreciation and amortization | 1,059,000 | 1,103,000 | |||||||
| Acquisition earnout valuation adjustments | (364,000 | ) | (500,000 | ) | |||||
| Provision for deferred income taxes | 39,000 | — | |||||||
| Share-based compensation expense | 572,000 | 326,000 | |||||||
| Provision for credit losses | — | 13,000 | |||||||
| Changes in assets and liabilities: | |||||||||
| Accounts and contract receivables | 3,900,000 | (678,000 | ) | ||||||
| Other assets | (15,000 | ) | 8,000 | ||||||
| Accounts payable | (327,000 | ) | 235,000 | ||||||
| Accrued expenses and other liabilities | (795,000 | ) | 739,000 | ||||||
| Deferred revenue | (1,042,000 | ) | 271,000 | ||||||
| Net cash provided by (used in) operating activities | 126,000 | (1,270,000 | ) | ||||||
| Cash flows from investing activities: | |||||||||
| Purchases of property and equipment | (29,000 | ) | — | ||||||
| Capitalization of software development costs | (404,000 | ) | (519,000 | ) | |||||
| Net cash used in investing activities | (433,000 | ) | (519,000 | ) | |||||
| Cash flows from financing activities: | |||||||||
| Repayment of bank term loan | (125,000 | ) | — | ||||||
| Payments related to settlement of employee share-based awards | (179,000 | ) | (141,000 | ) | |||||
| Net cash used in financing activities | (304,000 | ) | (141,000 | ) | |||||
| Net decrease in cash and cash equivalents | (611,000 | ) | (1,930,000 | ) | |||||
| Cash and cash equivalents at beginning of period | 6,598,000 | 9,885,000 | |||||||
| Cash and cash equivalents at end of period | $ | 5,987,000 | $ | 7,955,000 | |||||
STREAMLINE HEALTH SOLUTIONS, INC.
NEW BOOKINGS
(Unaudited, rounded to the nearest thousand dollars)
| April 30, 2023 | |||
| Three Months Ended | |||
| Software as a service | 2,076,000 | ||
| Maintenance and support | - | ||
| Professional fees and licenses | 98,000 | ||
| Q1 2023 Bookings | $ | 2,174,000 | |
| Q1 2022 Bookings* | $ | 8,863,000 | |
*Amount includes a single, 10-year contracted booking for RevID under the Company’s VAR with Cerner.
STREAMLINE HEALTH SOLUTIONS, INC.
RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited, in thousands)
| Three Months Ended | ||||||||
| April 30, 2023 | April 30, 2022 | |||||||
| Adjusted EBITDA Reconciliation | ||||||||
| Loss from continuing operations | $ | (2,901 | ) | $ | (2,787 | ) | ||
| Interest expense | 248 | 132 | ||||||
| Income tax expense | 53 | 11 | ||||||
| Depreciation and amortization | 1,031 | 1,083 | ||||||
| EBITDA | $ | (1,569 | ) | $ | (1,561 | ) | ||
| Share-based compensation expense | 572 | 326 | ||||||
| Non-cash valuation adjustments | (364 | ) | (500 | ) | ||||
| Acquisition-related cost, severance, and transaction-related bonuses | 57 | 501 | ||||||
| Other non-recurring expenses | (33 | ) | (48 | ) | ||||
| Adjusted EBITDA | $ | (1,337 | ) | $ | (1,282 | ) | ||
| Last Trade: | US$2.98 |
| Daily Change: | -0.42 -12.35 |
| Daily Volume: | 32,177 |
| Market Cap: | US$188.690M |
October 08, 2024 July 16, 2024 July 02, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
